Previous 10 | Next 10 |
2023-05-31 10:05:20 ET Gainers: Marker Therapeutics ( MRKR ) +34% . Nano-X Imaging ( NNOX ) +13% . Zai Lab ( ZLAB ) +9% . Invivyd ( IVVD ) +8% . Corbus Pharmaceuticals ( CRBP ) +7% . Losers: Belite Bio ( BLTE ) ...
2023-05-31 08:20:18 ET WANG & LEE GROUP ( WLGS ) +45% . Marker Therapeutics ( MRKR ) +37% Reports Pre-Clinical Data of its MT-601 MultiTAA-Specific T Cell Product Candidate in Lymphoma Cells. LL Flooring Holdings ( LL ) +20% jumps after founder offers...
SHANGHAI, China and CAMBRIDGE, Mass., May 25, 2023 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that members of the company’s senior management team will participate in the following investor conferences in June 2023: Jefferies Global Healthcare Co...
2023-05-22 11:11:09 ET Shares of several Chinese stocks moved higher today on Wall Street bullishness and after more positive comments made by President Joe Biden recently on U.S.-China relations. Shares of the large tech conglomerate Alibaba Group (NYSE: BABA) traded more than ...
2023-05-18 08:50:29 ET China's National Medical Products Administration (NMPA) granted priority review to Zai Lab's ( NASDAQ: ZLAB ) repotrectinib to treat adult patients with locally advanced or metastatic ROS1-positive non-small-cell lung cancer (NSCLC). A priority...
SHANGHAI, China and CAMBRIDGE, Mass., May 18, 2023 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that the Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) has granted priority review to repotrectinib for the treatm...
2023-05-10 14:08:07 ET Zai Lab Limited. (ZLAB) Q1 2023 Earnings Conference Call May 10, 2023, 08:00 AM ET Company Participants Billy Cho - Chief Financial Officer Samantha Du - Founder, Chairperson and Chief Executive Officer Josh Smiley - Chief Operating Officer...
2023-05-09 16:23:21 ET Zai Lab press release ( NASDAQ: ZLAB ): Q1 GAAP EPS of -$0.05 beats by $0.88 . Revenue of $62.79M (+34.4% Y/Y) misses by $2.68M . For further details see: Zai Lab GAAP EPS of -$0.05 beats by $0.88, revenue of $62.79M misses by $2.68M
Total product revenue of $62.8 million for the first quarter of 2023, representing a 36% increase y-o-y; ZEJULA® achieved 44% y-o-y growth Expansion of Zai Lab’s lung cancer franchise and global oncology pipeline with a next generation antibody-drug conjugate (ADC) program...
2023-04-27 09:17:33 ET Zai Lab ( NASDAQ: ZLAB ) signed a licensing agreement with MediLink Therapeutics for a next generation anti-body-drug conjugate (ADC) to treat cancer cancer. Zai said via the collaboration, it has expanded its lung cancer franchise and global oncology pi...
News, Short Squeeze, Breakout and More Instantly...
First and only NMPA-approved subcutaneous (SC) injectable providing additional flexibility and optionality for gMG patients in China Consistent clinical benefit and safety profile of efgartigimod SC compared to IV demonstrated in Phase 3 ADAPT-SC study Zai Lab Limited (NASDAQ: Z...
Manuscript represents the first publication from China’s gynecology oncology field to be published in Cell Publication highlights first-time learnings about the landscape of ovarian cancer microenvironment stratified by HRD and how a PARP inhibitor perturbs it Data suggest ...
2024-07-05 18:38:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...